Navigation Links
Surveyed U.S. and European Neurologists Agree that a Therapy's Effect on Physical Disability is the Most Important Attribute Influencing Prescribing Decisions in Secondary-Progressive Multiple Sclerosis

BURLINGTON, Mass., March 20, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European neurologists agree that a therapy's effect on physical disability is the most influential attribute when making prescribing decisions for secondary-progressive multiple sclerosis (SP-MS)*. These same neurologists cite a therapy's effect on quality of life as the second-most important attribute, ahead of an effect on relapses, imaging metrics and other functional domains.


Current management of SP-MS relies on the use of mainline disease-modifying therapies (which include interferon-betas and Teva's Copaxone), most of which are approved broadly for the treatment of relapsing forms of MS. This category encompasses relapsing-remitting MS (RR-MS) and SP-MS patients who continue to experience relapses. Interviewed thought leaders suggest that, based on data in RR-MS, Genzyme/Sanofi/Bayer HealthCare's Lemtrada may offer advantages over sales-leading Copaxone on measures of physical disability—potentially translating into clinical benefits for SP-MS patients. 

"The neurologists we surveyed indicate that an improved effect on physical disability is one of the greatest unmet needs in SP-MS," said Decision Resources Analyst Georgiana L. Kuhlmann , S.M. "Drawing on clinical data from RR-MS trials, interviewed thought leaders indicate that Lemtrada has demonstrated the potential to partially fulfill this unmet need."

According to the DecisionBase 2013 report entitled On What Attributes Will Neurologists and Payers Differentiate Novel Therapies for Secondary-Progressive Multiple Sclerosis?, surveyed managed care organization (MCO) pharmacy directors are receptive to new SP-MS therapies that offer improvements over current therapies on disability progression, as measured by the Expanded Disability Status Scale. Nine out of ten MCO pharmacy directors report a moderate to high willingness to grant preferred formulary status to a new SP-MS therapy offering improvements on disability progression; payers appear less inclined to grant similar status to products with improvements in other areas, particularly delivery.

"In our survey, 65 percent of MCO pharmacy directors are willing to reimburse a hypothetical therapy for the treatment of SP-MS that offers once daily oral delivery," Ms. Kuhlmann said. "However, additional study data suggest that improvements in delivery burden may be less likely than other achievements to translate into preferred formulary status."

*SP-MS and primary-progressive MS (PP-MS) comprise the chronic-progressive MS (CP-MS) population.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. According to Surveyed Oncologists in the EU5, Zytiga Has Heavily Penetrated Second-Line Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and is Displacing Jevtana to Later-Line mCRPC
2. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
3. Biodels Intellectual Property Position Strengthened for Ultra-Rapid-Acting Insulin Programs by Notice of Intent to Grant from European Patent Office
4. Marken Acquires European Kit Building Operation From LabCorp Clinical Trials
5. Blood Disorders: European Hematologists Gather in Amsterdam, June 14-17, 2012
6. Mylan Launches Generic Lipitor® in Five European Countries
7. European Thrombosis Therapeutics Market is Experiencing an Urgent Need for Enhanced Products, Says Frost & Sullivan
8. Bristol-Myers Squibb to Present New Data on ORENCIA(R)? (abatacept) at the European League Against Rheumatism (EULAR) 2012 Congress
9. Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion
10. Study Results of Novocures NovoTTF™ Pivotal Phase 3 Trial Published in European Journal of Cancer
11. Cardiac Dimensions® Announces Publication of TITAN Clinical Trial Data in European Journal of Heart Failure
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016 Revolutionary ... Oticon , industry leaders in advanced audiology ... of Oticon Opn ™, the world,s first internet ... possibilities for IoT devices.      (Photo: ... introduces a number of ,world firsts,: , ...
(Date:6/23/2016)... 2016 The vast majority of dialysis patients ... Treatments are usually 3 times a week, with treatment ... travel time, equipment preparation and wait time.  This regimen ... for patients who are elderly and frail.  Many elderly ... rehabilitation centers for some duration of time. ...
(Date:6/23/2016)... , June 23, 2016  Experian Health, ... and transforming the patient payment and care ... innovative new products and services that will ... revenue cycle offerings. These award-winning solutions will ... workflows, remain compliant in an ever-changing environment ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 27, 2016 , ... Quality metrics are proliferating in cancer care, and are ... the eye of the beholder, according to experts who offered insights and commentary in ... Managed Care. For the full issue, click here . , For the American ...
(Date:6/26/2016)... Clarkston, Michigan (PRWEB) , ... June 26, 2016 ... ... respect to fertility once they have been diagnosed with endometriosis. These women need ... but they also require a comprehensive approach that can help for preservation of ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are recognized ... this recognition are considered among the top 2 percent of lawyers practicing within the ... this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, Burt ...
Breaking Medicine News(10 mins):